Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system - Takeaways - MDSpire

Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system

  • By

  • José González Costello

  • Víctor Exposito Garcia

  • Eoin Moloney

  • Vasileios Kontogiannis

  • Mehdi Javanbakht

  • Farai Goromonzi

  • Brigitte Both

  • Raúl Moreno

  • May 29, 2026

  • 0 min

Share

  • 1

    The study evaluates the cost-utility of wearable cardioverter defibrillator (WCD) therapy plus guideline-directed medical therapy (GDMT) in Spain.

  • 2

    WCD plus GDMT projected gains of 0.53 life years and 0.43 quality-adjusted life years compared to GDMT alone.

  • 3

    Total lifetime costs for WCD plus GDMT were €113,290, with an incremental cost-effectiveness ratio of €26,145 per QALY gained.

  • 4

    The probability of cost-effectiveness for WCD therapy was 78.3% for patients during the early post-myocardial infarction period.

  • 5

    The analysis highlights the importance of patient selection and adherence for effective WCD therapy in high-risk post-MI patients.

Original Source(s)

Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system

  • by José González Costello, Víctor Exposito Garcia, Eoin Moloney, Vasileios Kontogiannis, Mehdi Javanbakht, Farai Goromonzi, Brigitte Both, Raúl Moreno

  • May 29, 2026

Related Content

Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk

Genetics of supraventricular tachycardia: current evidence with a focus on translational relevance and personalized medicine

The predictive value of platelet-to-high density lipoprotein cholesterol ratio and white blood cell-to-mean platelet volume ratio for coronary artery disease risk in STEMI patients